ACLS Stock Analysis: Axcelis Technologies | NASDAQ
Semiconductor Equipment & Materials | NASDAQ, USA | Market Cap: 4.160m USD | 12M Return: 37.4% | US0545402085 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 41.3M
EPS Trend: -96.3%
Qual. Beats: 1
Rev. Trend: -93.6%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Axcelis Technologies (ACLS) is a U.S.-based semiconductor equipment manufacturer founded in 1978 and headquartered in Beverly, Massachusetts. The company specializes in ion implantation systems-a critical process step in semiconductor chip fabrication used to modify the electrical properties of silicon wafers through doping. Its product portfolio includes high energy, high current, and medium current implanters designed to meet varied application requirements.
In addition to new equipment sales via a direct sales force, Axcelis generates recurring revenue through an aftermarket lifecycle business that supplies used tools, spare parts, equipment upgrades, maintenance services, and customer training. The company serves chip manufacturers across the United States, Europe, and the Asia Pacific region, positioning it within the Semiconductor Materials & Equipment sub-industry of the Information Technology sector.
- SiC power device adoption accelerates ion implanter orders
- Aftermarket services revenue expands with growing installed base
- China chipmaker capex exposed to tightening export controls
| Net Income: 92.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -4.53 > 1.0 |
| NWC/Revenue: 90.02% < 20% (prev 99.03%; Δ -9.00% < -1%) |
| CFO/TA 0.05 > 3% & CFO 75.3m > Net Income 92.8m |
| Net Debt (-360.6m) to EBITDA (127.7m): -2.82 < 3 |
| Current Ratio: 4.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.1m) vs 12m ago -3.02% < -2% |
| Gross Margin: 43.01% > 18% (prev 44.90%; Δ -1.88% > 0.5%) |
| Asset Turnover: 63.91% > 50% (prev 67.71%; Δ -3.80% > 0%) |
| Interest Coverage Ratio: 21.18 > 6 (EBIT TTM 110.0m / Interest Expense TTM 5.20m) |
| A: 0.56 (Total Current Assets 979.8m - Total Current Liabilities 200.1m) / Total Assets 1.39b |
| B: 0.39 (Retained Earnings 536.0m / Total Assets 1.39b) |
| C: 0.08 (EBIT TTM 110.0m / Avg Total Assets 1.36b) |
| D: 3.32 (Book Value of Equity 1.07b / Total Liabilities 321.0m) |
| Altman-Z'' = 8.98 = AAA |
| DSRI: 1.15 (Receivables 154.1m/138.8m, Revenue 866.1m/896.1m) |
| GMI: 1.04 (GM 44.90% / 43.01%) |
| AQI: 1.86 (AQ_t 0.22 / AQ_t-1 0.12) |
| SGI: 0.97 (Revenue 866.1m / 896.1m) |
| TATA: 0.01 (NI 92.8m - CFO 75.3m) / TA 1.39b) |
| Beneish M = -2.38 (Cap -4..+1) = BBB |
As of October 16, 2026, the stock is trading at USD 115.11 with a total of 410,400 shares traded. Over the past week, the price has changed by -13.76%, over one month by +9.59%, over three months by -20.62% and over the past year by +37.41%.
Current recommended Stop Loss: 107.20 (which is 6.9% or 1.3 ATR below the current price).
Axcelis Technologies has received a consensus analysts rating of 3.20. Therefore, it is recommended to hold ACLS.
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 161 | 39.9% |
P/E Trailing = 45.2047
P/E Forward = 19.8413
P/S = 4.8033
P/B = 3.3515
P/EG = 1.4493
Revenue TTM = 866.1m USD
EBIT TTM = 110.0m USD
EBITDA TTM = 127.7m USD
Long Term Debt = 40.8m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 1.72m USD (from shortTermDebt, last quarter)
Debt = 41.6m USD (from shortLongTermDebtTotal, last quarter) (leases 41.6m already included)
Net Debt = -360.6m USD (calculated: Debt 41.6m - CCE 402.2m)
Enterprise Value = 3.80b USD (4.16b + Debt 41.6m - CCE 402.2m)
Interest Coverage Ratio = 21.18 (Ebit TTM 110.0m / Interest Expense TTM 5.20m)
EV/FCF = 57.96x (Enterprise Value 3.80b / FCF TTM 65.6m)
FCF Yield = 1.73% (FCF TTM 65.6m / Enterprise Value 3.80b)
FCF Margin = 7.57% (FCF TTM 65.6m / Revenue TTM 866.1m)
Net Margin = 10.71% (Net Income TTM 92.8m / Revenue TTM 866.1m)
Gross Margin = 43.01% ((Revenue TTM 866.1m - Cost of Revenue TTM 493.6m) / Revenue TTM)
Gross Margin QoQ = 42.38% (prev 40.50%)
Tobins Q-Ratio = 2.74 (Enterprise Value 3.80b / Total Assets 1.39b)
Interest Expense / Debt = 12.50% (Interest Expense 5.20m / Debt 41.6m)
Taxrate = 12.58% (13.4m / 106.1m)
NOPAT = 96.2m (EBIT 110.0m * (1 - 12.58%))
Current Ratio = 4.90 (Total Current Assets 979.8m / Total Current Liabilities 200.1m)
Debt / Equity = 0.04 (Debt 41.6m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = -2.82 (Net Debt -360.6m / EBITDA 127.7m)
Debt / FCF = -5.50 (Net Debt -360.6m / FCF TTM 65.6m)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.85% (Net Income 92.8m / Total Assets 1.39b)
RoE = 8.91% (Net Income TTM 92.8m / Total Stockholder Equity 1.04b)
RoCE = 10.17% (EBIT 110.0m / Capital Employed (Equity 1.04b + L.T.Debt 40.8m))
RoIC = 8.40% (NOPAT 96.2m / Invested Capital 1.15b)
WACC = 15.14% (E(4.16b)/V(4.20b) * Re(15.18%) + D(41.6m)/V(4.20b) * Rd(12.50%) * (1-Tc(0.13)))
Discount Rate = 15.18% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: -96.60 | Cagr: -2.46%
[DCF] Terminal Value 52.19% ; FCFF base≈88.4m ; Y1≈77.5m ; Y5≈62.6m
[DCF] Fair Price = 27.25 (EV 480.7m - Net Debt -360.6m = Equity 841.4m / Shares 30.9m; r=15.14% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -96.34 | EPS CAGR: -19.62% | SUE: 1.01 | # QB: 1
Revenue Correlation: -93.59 | Revenue CAGR: -11.97% | SUE: 1.50 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.11 | Chg30d=+6.35% | Revisions=+57% | Analysts=5
EPS current Year (2026-12-31): EPS=4.11 | Chg30d=+7.09% | Revisions=+57% | GrowthEPS=-15.9% | GrowthRev=+5.3%
EPS next Year (2027-12-31): EPS=5.27 | Chg30d=+8.66% | Revisions=+0% | GrowthEPS=+28.3% | GrowthRev=+11.9%
[Analyst] Revisions Ratio: +53% (up=10, down=2)